脑机接口海内外共振，20cm涨跌幅产品科创创新药ETF（589720）涨超5%

Group 1 - Neuralink, founded by Elon Musk, plans to start large-scale production of brain-computer interface devices in 2026, transitioning to fully automated surgical processes [1][3] - The first medical device industry standard for brain-computer interfaces in China will be implemented on January 1, 2026, laying the foundation for standardized industry development [3] - The brain-computer interface sector is expected to see significant growth, with major players like Strong Brain Technology and Borui Kang entering pre-IPO financing [3] Group 2 - The small nucleic acid drug sector is gaining momentum, with Rebio Biotechnology set to list on the Hong Kong stock market, further boosting market sentiment [4] - Small nucleic acid drugs are expanding their therapeutic boundaries by regulating pathological processes at the genetic level [4] - The global small nucleic acid drug field is experiencing significant advancements, transitioning from concept validation to industrial emergence, driven by breakthroughs in delivery technology and commercialization of key products [7] Group 3 - Zai Lab has reached a strategic collaboration with AbbVie for ZG006, with an upfront payment of $100 million and a total deal value of up to $1.075 billion plus sales royalties, indicating global recognition of the product's value [5] - The valuation of innovative drug assets is undergoing continuous recovery, with a rising number of domestic original drugs being approved, rapidly capturing market share across various therapeutic areas [5] - The trend of domestic innovative drugs "going global" is injecting new momentum into the sector, with overseas licensing transaction amounts reaching new highs [5] Group 4 - The innovative drug ETF (589720) has outperformed Hong Kong's innovative drug sector by nearly 10 percentage points since the 924 market rally, showcasing higher performance recovery elasticity [10][11] - The ETF focuses on high-growth biotech companies and is designed to align closely with sector volatility, with a 20% daily price fluctuation limit [10] - Key upcoming events, such as the JPM conference in mid-January and the ASCO annual meeting in May, are expected to disclose critical clinical data, which could drive capital inflow into the innovative drug sector [10]